Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously

NCT ID: NCT04594850

Last Updated: 2024-04-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-19
• Study Completion Date: 2026-01-31

Brief Summary

This phase II clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Detailed Description

To evaluate the efficacy and efficacy for 12 months after a single dose of Cellgram-ED in patients with erectile dysfunction after radical prostatectomy.

Conditions

Erectile Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Placebo-Control group

Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Injection group: Cellgram-ED

Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand.

Group Type: EXPERIMENTAL

Cellgram-ED

Intervention Type: BIOLOGICAL

Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.

Interventions

Cellgram-ED

Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.

Intervention Type: BIOLOGICAL

Other Intervention Names

Autologous bone marrow derived mesenchymal stem cell

Eligibility Criteria

Inclusion Criteria

1. Men aged 19 to 80 years old at screening

2. Patients who maintained normal foot function before prostatectomy and are interested in restoring sexual function after surgery

3. PSA level <10 ng/mL before prostatectomy

4. Pathological Gleason sum ≤ 7(3+4 or 4+3) factor during prostatectomy

5. Local lesions that did not metastasize during prostatectomy (pT2, N0, M0 stage) factors

6. Patients more than 1 year after prostatectomy and PSA ≤ 0.04 ng/mL when screened without additional treatment other than surgery

7. Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks.

8. Total score of 10 or more and 17 or less in the EF (Erectile function) field* of the International Erectile Function Questionnaire

• 1, 2, 3, 4, 5, 15 questions for EF erectile function in the international erectile function questionnaire

9. Prevalence for erectile dysfunction at screening with more than 6 months

10. Who are willing to engage in sexual activity more than 4 times a month and have a constant partner for at least 3 months

11. Who do not have difficulty reading and understanding the contents of the questionnaire and who fill out a complete questionnaire

12. A person who voluntarily agrees to participate in this clinical trial and has signed the consent form by the subject and the subject partner

1. Total score of 10 or more and 17 or less in the EF (Erectile function) field* of the International Erectile Function Questionnaire (IIEF)

• 1, 2, 3, 4, 5, 15 questions for EF erectile function in the international erectile function questionnaire

2. Who attempts sexual activity more than 4 times during the run-in period and has a failure rate (Sexual Encounter Profile) of 50% or more

Exclusion Criteria

1. Severe cardiovascular disease (angina pectoris, myocardial infarction, unstable arrhythmia, heart failure, etc.) at the screening visit

2. Who cannot collect bone marrow due to bone marrow disease, etc.

3. Those with the following medical history/companion diseases A. Gentamicin hypersensitivity reaction B. Solid cancer or malignant blood disease within 5 years prior to screening C. Clinically significant cognitive impairment, dementia or psychiatric disorder D. Alcohol or substance abuse E. Priapism F. Severe respiratory diseases (COPD, asthma, pneumonia, pulmonary embolism, pneumothorax, etc.) G. Stroke H. Systemic autoimmune disease

4. Those with the following test results at the screening visit A. Liver disease or abnormal liver function (AST or ALT ≥ 3 times the normal upper limit of the organ) B. Severe renal impairment (serum creatinine≥ 2 mg/dL) C. Positive factors for pathogenic microbial tests (Hbs Ag, HCV Ab, HIV Ab, Syphilis) D. Uncontrolled high blood pressure (systolic blood pressure >170 mmHg or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure <90 mmHg, diastolic blood pressure <50 mmHg) E. Who are outside the normal range of tumor marker tests (PSA, CEA, AFP) F. Hemorrhagic tendency (PT and aPTT> ULN x 1.5) G. Untreated hypogonadism or serum testosterone hormone less than 200 ng/dL

5. Those who possess the following therapeutic powers at screening A. Who are being treated for severe systemic or local infection B. Long-term use of anticoagulant (warfarin) (administered for more than 3 months as anticoagulant therapy) C. Vacuum compressor or intracavernous injection therapy within 7 days before screening (prostaglandin E1, papaverine, phentolamine, etc.) D. Immunosuppressants, alpha blockers or male hormones (androgens, anti-androgens) within 28 days prior to screening

6. Penile anatomical malformations (ex: Peyronie's disease) or penile implants or penile vascular procedures

7. Who are receiving drugs* that are expected to affect the results of this clinical trial when judged by the investigator

8. If the partner is a woman of childbearing potential, those who are not willing to use an appropriate contraceptive method** during the clinical trial period

**Contraceptive administration and implantation or intrauterine device, infertility procedures (vapectomy, tubal ligation, etc.), blocking method (condom, contraceptive diaphragm, vaginal sponge or cervical cap)

9. Who participated in other interventional clinical trials within 4 weeks prior to the screening visit and received clinical investigational drugs/investigational medical devices or received procedures

10. Who have or will be administered other cell therapy products

11. A person who is judged to be inappropriate to participate in this test when judged by the examiner

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Pharmicell Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chungsu Kim, Ph.D

Role: PRINCIPAL_INVESTIGATOR

AIDS Malignancy Consortium

Locations

Asan medical center

Seoul, , South Korea

Site Status: RECRUITING

Ewha womans university medical center

Seoul, , South Korea

Site Status: RECRUITING

Samsung medical center

Seoul, , South Korea

Site Status: RECRUITING

Seoul ST. Mary's hospital

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

DAEUN JUNG

Role: CONTACT

daeun4100@pharmicell.com

82-2-3496-0134

Facility Contacts

Dalsan You, PhD

Role: primary

dalsanyou@amc.seoul.kr

82-2-3010-3979

Chungsu Kim, Ph.D

Role: primary

cskim37345806@gmail.com

Seongwon Lee

Role: primary

Jiyoul Lee, Ph.D

Role: primary

Other Identifiers

PMC-P-10

Identifier Type: -

Identifier Source: org_study_id